Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience
Abstract
Introduction: Lung cancer is the most common cause of cancer-related death in the world. Changes in the treatment of metastatic lung cancer in recent years have made targetable mutations gain importance. MET alteration is one of these driver mutations and crizotinib is a tyrosine kinase inhibitor used in therapy.
Collections
- Makale [92796]